COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,050 Articles (22,627 medRxiv, 8,423 bioRxiv)

Most recent first Previous |  Page 1930: Articles 19291-19300  | Next

SARS-CoV-2 RNA quantification using droplet digital RT-PCR
Kinloch, N. N., Ritchie, G., Dong, W., Cobarrubias, K. D., Sudderuddin, H., Lawson, T., Matic, N., Montaner, J. S. G., Leung, V., Romney, M. G., Lowe, C. F. J., Brumme, C. J., Brumme, Z. L.
10.1101/2020.12.21.423898 — Posted: 2020-12-23
Active learning tools improve the learning outcomes, scientific attitude and critical thinking in higher education: Experiences in an online course during the COVID-19 pandemic
Rossi, I. V., de Lima, J. D., Sabatke, B., Nunes, M. A. F., Ramirez, G. E., Ramirez, M. I.
10.1101/2020.12.22.423922 — Posted: 2020-12-22
Analysis of 46,046 SARS-CoV-2 whole-genomes leveraging principal component analysis (PCA)
Scherer, C., Grover, J., Kameraad, D., Rudy, G., Scherer, A.
10.1101/2020.12.20.423682 — Posted: 2020-12-22
Content analysis and characterization of medical tweets during the early Covid-19 pandemic
Prager, R., Pratte, M., Unni, R. R., Bala, S., Ng Fat Hing, N., Wu, K., McGrath, T. A., Thomas, A., Thompson, L. H., Hajjar, J., Thoma, B., Rola, P., Karovitch, A., Kyeremanteng, K.
10.1101/2020.12.22.20248712 — Posted: 2020-12-22
COVID-19 Network Model to Evaluate Vaccine Strategies towards Herd Immunity
Tetteh, J. N. A., Nguyen, V. K., Hernandez Vargas, E. A.
10.1101/2020.12.22.20248693 — Posted: 2020-12-22
A comparative analysis of COVID-19 mortality rate across the globe: An extensive analysis of the associated factors
Jain, V., Nabi, , N., Chandra, K., Irshad, S., kashyap, V., Kohli, S., Gupta, A.
10.1101/2020.12.22.20248696 — Posted: 2020-12-22
Is Fear of COVID-19 Higher among Food-Insecure Households? A Model-Based Study, Mediated by Perceived Stress among Iranian Populations
Ezzeddin, N., Eini-Zinab, H., Kalantari, N., Ahmadi, M., Beheshti, Z.
10.1101/2020.12.22.20248714 — Posted: 2020-12-22
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report
Ella, R., Reddy, S., Jogdand, H., Sarangi, V., Ganneru, B., Prasad, S., Das, D., Raju, D., Praturi, U., Sapkal, G., Yadav, P., Reddy, P., Verma, S., Singh, C., Redkar, S. V., Gillurkar, C. S., Kushwaha, J. S., Mohapatra, S., Rai, S. K., Bhate, A., Panda, S., Abraham, P., Gupta, N., Ella, K., Bhargava, B., Vadrevu, K. M.
10.1101/2020.12.21.20248643 — Posted: 2020-12-22 Discussion: Onsite | Offsite
Analyzing the vast coronavirus literature with CoronaCentral
Lever, J., Altman, R. B.
10.1101/2020.12.21.423860 — Posted: 2020-12-22
T cell activation, highly armed cytotoxic cells and a sharp shift in monocytes CD300 receptors expression is characteristic of patients with severe COVID-19
Zenarruzabeitia, O., Astarloa-Pando, G., Terren, I., Orrantia, A., Perez-Garay, R., Seijas-Betolaza, I., Nieto-Arana, J., Imaz-Ayo, N., Perez-Fernandez, S., Arana-Arri, E., Borrego, F.
10.1101/2020.12.22.423917 — Posted: 2020-12-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).